Literature DB >> 18567001

Inhibition of melanogenesis as a radiation sensitizer for melanoma therapy.

Anna A Brozyna1, Lester VanMiddlesworth, Andrzej T Slominski.   

Abstract

Melanin pigment displays strong photo- and radioprotective properties, suggesting that inhibition melanogenesis could increase sensitivity of melanoma to ionizing radiation. We tested this concept in human melanoma cells cultured in either Ham's F10 medium to maintain amelanotic phenotype or DMEM to induce/stimulate melanin production, respectively; N-phenylthiourea (PTU) and D-penicillamine were used as an inhibitor of melanogenesis. Melanogenic activity was evaluated by visual inspection (color of cell pellets) or by measurement of tyrosinase (dopa oxidase) activity assay. Amelanotic cells or cells with various melanin content were exposed to gamma radiation and tested for viability and colony forming capability. Gamma radiation at doses of 2-15 Gy inhibited cell viability and colony forming efficiency in dose- and time-dependent manner, but pigmented melanoma cells were significantly more resistant to gamma radiation than nonpigmented cells (p < 0.05-0.001). Both PTU and D-penicillamine inhibited strongly tyrosinase activity and melanin production in melanoma cells (p < 0.05-0.001). Furthermore, inhibition of melanogenesis by PTU or D-penicillamine resulted in enhancement of melanoma cells sensitivity to killing by gamma rays. In conclusion, the results of these cell culture experiments give support to a clinical trial of pharmacologically induced decrease in melanin synthesis to enhance the efficacy of radiotherapy in advanced melanomas. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18567001     DOI: 10.1002/ijc.23664

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  60 in total

1.  Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy.

Authors:  Jessica D Knoll; Claudia Turro
Journal:  Coord Chem Rev       Date:  2015-01-01       Impact factor: 22.315

2.  Behaviour of four different B16 murine melanoma cell sublines: C57BL/6J skin.

Authors:  Corina Danciu; Camelia Oprean; Dorina E Coricovac; Cioca Andreea; Anca Cimpean; Heinfried Radeke; Codruta Soica; Cristina Dehelean
Journal:  Int J Exp Pathol       Date:  2015-02-09       Impact factor: 1.925

3.  From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis.

Authors:  Aikaterini F Giannopoulou; Athanassios D Velentzas; Athanasios K Anagnostopoulos; Adamantia Agalou; Nikos C Papandreou; Stamatia A Katarachia; Dimitra G Koumoundourou; Eumorphia G Konstantakou; Vasiliki I Pantazopoulou; Anastasios Delis; Maria T Michailidi; Dimitrios Valakos; Dimitris Chatzopoulos; Popi Syntichaki; Vassiliki A Iconomidou; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Polydefkis Hatzopoulos; Dimitris Thanos; Dimitris Beis; Ema Anastasiadou; George Th Tsangaris; Dimitrios J Stravopodis
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

Review 4.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 5.  Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma.

Authors:  Sarah Sammons; Donita Brady; Linda Vahdat; April Ks Salama
Journal:  Melanoma Manag       Date:  2016-09-02

6.  Melatonin exerts oncostatic capacity and decreases melanogenesis in human MNT-1 melanoma cells.

Authors:  Konrad Kleszczyński; Tae-Kang Kim; Bernadetta Bilska; Michal Sarna; Krystian Mokrzynski; Agatha Stegemann; Elżbieta Pyza; Russel J Reiter; Kerstin Steinbrink; Markus Böhm; Andrzej T Slominski
Journal:  J Pineal Res       Date:  2019-10-07       Impact factor: 13.007

7.  Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy.

Authors:  Pawel Mroz; Ying-Ying Huang; Angelika Szokalska; Timur Zhiyentayev; Sahar Janjua; Artemissia-Phoebe Nifli; Margaret E Sherwood; Christian Ruzié; K Eszter Borbas; Dazhong Fan; Michael Krayer; Thiagarajan Balasubramanian; Eunkyung Yang; Hooi Ling Kee; Christine Kirmaier; James R Diers; David F Bocian; Dewey Holten; Jonathan S Lindsey; Michael R Hamblin
Journal:  FASEB J       Date:  2010-04-12       Impact factor: 5.191

8.  Targeting protein-trafficking pathways alters melanoma treatment sensitivity.

Authors:  Zhi-ming Huang; Milka Chinen; Philip J Chang; Tong Xie; Lily Zhong; Stephanie Demetriou; Mira P Patel; Rebecca Scherzer; Elena V Sviderskaya; Dorothy C Bennett; Glenn L Millhauser; Dennis H Oh; James E Cleaver; Maria L Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-27       Impact factor: 11.205

9.  The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways.

Authors:  A Slominski; T-K Kim; A A Brożyna; Z Janjetovic; D L P Brooks; L P Schwab; C Skobowiat; W Jóźwicki; T N Seagroves
Journal:  Arch Biochem Biophys       Date:  2014-07-02       Impact factor: 4.013

10.  Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy.

Authors:  Tomoaki Takada; Toshiharu Yamashita; Makito Sato; Akiko Sato; Ichiro Ono; Yasuaki Tamura; Noriyuki Sato; Atsushi Miyamoto; Akira Ito; Hiroyuki Honda; Kazumasa Wakamatsu; Shosuke Ito; Kowichi Jimbow
Journal:  J Biomed Biotechnol       Date:  2009-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.